Yuhan Corp
KRX:000100

Watchlist Manager
Yuhan Corp Logo
Yuhan Corp
KRX:000100
Watchlist
Price: 115 100 KRW -1.79% Market Closed
Market Cap: 8.5T KRW
Have any thoughts about
Yuhan Corp?
Write Note

Yuhan Corp
Intangible Assets

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Yuhan Corp
Intangible Assets Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Intangible Assets CAGR 3Y CAGR 5Y CAGR 10Y
Yuhan Corp
KRX:000100
Intangible Assets
â‚©169.8B
CAGR 3-Years
28%
CAGR 5-Years
44%
CAGR 10-Years
31%
SK Biopharmaceuticals Co Ltd
KRX:326030
Intangible Assets
â‚©23.6B
CAGR 3-Years
6%
CAGR 5-Years
149%
CAGR 10-Years
N/A
Hanmi Science Co Ltd
KRX:008930
Intangible Assets
â‚©65.6B
CAGR 3-Years
104%
CAGR 5-Years
44%
CAGR 10-Years
29%
Hanmi Pharm Co Ltd
KRX:128940
Intangible Assets
â‚©85.3B
CAGR 3-Years
4%
CAGR 5-Years
6%
CAGR 10-Years
0%
S
Sam Chun Dang Pharm Co Ltd
KOSDAQ:000250
Intangible Assets
â‚©105.4B
CAGR 3-Years
47%
CAGR 5-Years
40%
CAGR 10-Years
45%
C
Celltrion Pharm Inc
KOSDAQ:068760
Intangible Assets
â‚©6.1B
CAGR 3-Years
-1%
CAGR 5-Years
14%
CAGR 10-Years
-11%
No Stocks Found

Yuhan Corp
Glance View

Market Cap
8.5T KRW
Industry
Pharmaceuticals

Yuhan Corp., a leading player in South Korea's pharmaceutical industry, has a rich history dating back to its founding in 1926. The company has successfully built a strong reputation for innovation and reliability, developing a diverse portfolio that includes prescription drugs, over-the-counter medications, and biopharmaceuticals. Yuhan stands out not only for its robust domestic market presence but also for its strategic global partnerships, which have allowed it to expand its reach and enhance its product offerings. Investors can appreciate Yuhan's focus on research and development, as evidenced by its significant investment in cutting-edge therapies and advanced drug formulations that cater to unmet medical needs. In recent years, Yuhan Corp. has intensified its commitment to growth through collaborations with international companies, enhancing its capabilities in areas such as oncology, autoimmune disorders, and neurology. These partnerships position Yuhan well to capitalize on global market trends and shifting healthcare demands, offering promising avenues for revenue generation. As an investor, one would find comfort in Yuhan's strong financial performance, characterized by steady revenue growth, increasing profitability, and prudent cost management. With a forward-looking vision and a solid foundation, Yuhan Corp. represents a compelling opportunity for those interested in tapping into the thriving pharmaceutical sector and benefiting from innovations that improve healthcare outcomes globally.

Intrinsic Value
54 100.21 KRW
Overvaluation 53%
Intrinsic Value
Price

See Also

What is Yuhan Corp's Intangible Assets?
Intangible Assets
169.8B KRW

Based on the financial report for Sep 30, 2024, Yuhan Corp's Intangible Assets amounts to 169.8B KRW.

What is Yuhan Corp's Intangible Assets growth rate?
Intangible Assets CAGR 10Y
31%

Over the last year, the Intangible Assets growth was 5%. The average annual Intangible Assets growth rates for Yuhan Corp have been 28% over the past three years , 44% over the past five years , and 31% over the past ten years .

Back to Top